JAZZ250117C175000
- 0.00
- 0.000.00%
Jazz Pharmaceuticals Newsroom
Executive Reshuffles: BA, EXPE, TPVG and GEO
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $195
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $195
Jazz Pharmaceuticals (JAZZ) Gets a Buy From TD Cowen
Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24...
Express News | Jazz Pharmaceuticals PLC - Bruce Cozadd to Retire as CEO by End of 2025
Express News | Jazz Pharmaceuticals Outlook FY Revenue USD 4,000-4,100 Million
Express News | Jazz Pharmaceuticals Announces CEO Succession Plan
Press Release: Jazz Pharmaceuticals Announces CEO Succession Plan
Sentiment Still Eluding Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $163 to $230
Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $163
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207